Why this ASX 200 'stable stock' is poised to outperform: Goldman Sachs

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing.

| More on:
A mature age woman with a groovy short haircut and glasses, sits at her computer, pen in hand thinking about information she is seeing on the screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 200 Index (ASX: XJO) healthcare share ResMed Inc (ASX: RMD) counts among a select basket of stable stocks that Goldman Sachs believes is set to widely outperform the benchmark.

The company is listed on multiple international exchanges. It focuses on treating a range of sleeping disorders and has seen some sizeable swings its share price over the past year, leaving it right about where it was 12 months ago.

But the ASX 200 medical stock could enjoy a far stronger year ahead.

14% potential share price upside for ResMed

According to analysts at Goldman Sachs, stocks with stable earnings growth and share prices have historically tended to outperform when the economy is slowing. But we've yet to see that with Goldman's basket of stable stocks, which includes ResMed.

"Our economists see greater downside risks than upside risks, suggesting ample opportunities for stable stocks to outperform," the analysts said (courtesy of The Australian Financial Review.)

The broker said that despite the economic slowdown hitting developed nations, stables stocks — like ASX 200 listed ResMed — are trading at "undemanding valuations".

There are no guarantees in the world of investing. But Goldman sees a positive risk-reward trade-off with ResMed shares.

The main risk to owning stable stocks is if economic growth proves to be more resilient than we expect," the broker said. "But low valuations, poor recent performance, and elevated recession risk mean the risk/reward is asymmetric."

In its recent report profiling a range of ASX 200 healthcare stocks, Goldman noted:

We continue to express a general preference for the device/drug names over the service providers in the current environment, on the basis of: i) stronger pricing power; ii) more assured volume profiles; iii) more resilient/expanding market shares; and iv) stronger balance sheets.

As for ResMed specifically, the analysts said, "As operational pressures continue to ease we see margin/cost dynamics improving, both near and long-term."

Goldman is expecting "a sequentially stronger 2H23" for the ASX 200 medical device stock. The analysts forecast an earnings per share compound annual growth rate of 11% over the next three years "with potential upside depending on how competitive dynamics develop".

Sharper-than-expected competitor recovery and potentially new disruptive therapies are the key risks to this outlook.

Goldman has a buy rating on ResMed shares with a target price of $38.00. That's 13.8% above the current share price.

How has this ASX 200 stable stock been tracking?

As you can see in the chart below, the ResMed share price is just about flat over the past 12 months. So far in 2023, the ASX 200 stable stock has gained 7.8%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »